Wolterman Dan
Known title: DirectorCIK: 0001586330
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Hyperfine Expands Portable Brain MRI Reach to Gulf Markets. Hyperfine has announced that its portable brain MRI system will now be available in key Gulf Cooperation Council countries, expanding its global footprint. The move follows the company’s recent rollout in other international markets and could increase adoption in the region’s hospitals. BTIG has reiterated a bullish stance, keeping its $2 price target unchanged. These developments highlight growing interest in Hyperfine’s technology.
Transaction History
| GMED | ▲ Buy | Grant | 24,025 | — | 9/1/2023 | View on chart |
| HYPR | ▲ Buy | Grant | 16,483 | $0 | 12/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RBC Lowers Globus Medical Price Target to $85
RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.
RBC Lowers Globus Medical Price Target to $85. RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.